您的位置: 首页 > 2019年3月 第50卷 第2期 > 文字全文
2023年7月 第38卷 第7期11
目录

2型糖尿病肾病患者血清Chemerin与SOD、MDA的临床分析

Analysis between plasma chemerin and SOD、MDA in patients with Type 2 diabetic nephropathy

来源期刊: 广州医药 | 7-10 发布时间:2021-12-17 收稿时间:2025/11/13 17:32:10 阅读量:30
作者:
关键词:
糖尿病肾病ChemerinSODMDA
Diabetic nephropathyChemerinSuperoxidedismutase (SOD)Malondiadehyde (MDA)
DOI:
10.3969/j.issn.1000-8535.2019.02.002
收稿时间:
2018-12-13 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 本研究旨在探讨2型糖尿病不同程度肾病与chemerin、SOD及MDA的相关性。方法 选取2016年1月—2017年12月期间于广州市第一人民医院内分泌科门诊和住院的患者100例,根据尿白蛋白/肌酐比(ACR)分为正常尿蛋白组(NA组,n=33),微量白蛋白尿组(MA组,n=34)及大量蛋白尿组(CA组,n=33),另选取32例我院体检中心体检结果正常的正常健康人作为对照组(NC组,n=32),测定血糖、糖化血红蛋白、血肌酐、ACR、24小时尿蛋白定量、胆固醇、甘油三酯、SOD、MDA、chemerin等水平。结果 SOD的水平:NC组> NA组> MA组>CA组(P<0.05);MDA的水平:CA组>MA组>NA组>NC组(P<0.05);Chemerin水平:CA组>MA组>NA组>NC组(P<0.05)。相关性分析提示ACR与血清SOD呈负相关,与MDA、chemerin呈正相关。多元回归分析显示,病程、胆固醇、糖化血红蛋白、chemerin是影响ACR的主要因素。结论 Chemerin、MDA、SOD可能参与糖尿病肾病的发生发展,检测其水平可以在一定程度上反映2型糖尿病肾病患者的病情严重程度。
Objective To explore the relationship between different type of Type 2 diabetes nephropathy and chemerin,SOD,MDA. Methods A total of 100 inpatients and outpatients were enrolled in this study between January 2016 and December 2017 in Guangzhou First People's Hospital. They were divided into normal urinary protein group (NA group, n=33), microalbuminuria group (MA group, n=34) and massive proteinuria group (CA group, n=33) based on ACR. Another 32 healthy people were collected as a control group in medical examination center (NC group, n=32). The levels of blood sugar, glycated hemoglobin, serum creatinine, ACR, 24-hour urinary protein, cholesterol, triglyceride, SOD, MDA and chemerin were measured. Results The level of SOD: NC group > NA group > MA group > CA group (P< 0.05). The level of MDA: CA group > MA group > NA group > NC group (P< 0.05). The level of chemerin: CA group > MA group > NA group > NC group (P< 0.05). Correlation analysis showed that ACR was negatively correlated with serum SOD and positively correlated with MDA and chemerin. Multivariate logistic regression demonstrated that course of disease, CHOL, HbA1c and chemerin were the main factors affecting ACR. Conclusion Chemerin, MDA and SOD may be involved in the occurrence and development of diabetic nephropathy. Chemerin, MDA and SOD may reflect the severity of type 2 diabetic nephropathy
1、 ZYLLA S, RETTIG R, VOLZKE H, et al. Serum chemerin levels are inversely associated with renal function in a general population[J]. Clin Endocrinol (Oxf), 2018,88(1): 146-153. ZYLLA S, RETTIG R, VOLZKE H, et al. Serum chemerin levels are inversely associated with renal function in a general population[J]. Clin Endocrinol (Oxf), 2018,88(1): 146-153.
2、 FATIMA A S, BUTT Z, BADER N, et al. Role of multifunctional Chemerin in obesity and preclinical diabetes[J]. Obes Res Clin Pract, 2015, 9(5): 507-512. FATIMA A S, BUTT Z, BADER N, et al. Role of multifunctional Chemerin in obesity and preclinical diabetes[J]. Obes Res Clin Pract, 2015, 9(5): 507-512.
3、 TABAK O, GELISGEN R, Erman H, et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. [J]. Clin Invest Med, 2011, 34(3): E163-171. TABAK O, GELISGEN R, Erman H, et al. Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. [J]. Clin Invest Med, 2011, 34(3): E163-171.
4、 Sun Y M. Study of SOD and PON-1 expression in type 2 diabetes mellitus nephropathy and its clinical significance[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2010, 26(11): 1120-1121. Sun Y M. Study of SOD and PON-1 expression in type 2 diabetes mellitus nephropathy and its clinical significance[J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2010, 26(11): 1120-1121.
5、 SUSZTAK K, RAFF A C, SCHIFFER M. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy[J]. Diabetes, 2006, 55(1): 225-233. SUSZTAK K, RAFF A C, SCHIFFER M. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy[J]. Diabetes, 2006, 55(1): 225-233.
6、 蔡文娟. 尿微量白蛋白/肌酐比值对糖尿病肾病早期诊断价值 [J]. 中国实验诊断学, 2013, 17(9): 1650-1653. 蔡文娟. 尿微量白蛋白/肌酐比值对糖尿病肾病早期诊断价值 [J]. 中国实验诊断学, 2013, 17(9): 1650-1653.
7、 陈浩雄. 2型糖尿病肾病患者肾组织中 STOML2的表达及作用 [J]. 广州医药, 2016, 4(47): 42-45. 陈浩雄. 2型糖尿病肾病患者肾组织中 STOML2的表达及作用 [J]. 广州医药, 2016, 4(47): 42-45.
8、 刘媛媛. 血管紧张素转化酶基因插入/缺失多态性与糖尿病肾病相关性的研究进展[J]. 中日友好医院学报,2018,32(1):42-44. 刘媛媛. 血管紧张素转化酶基因插入/缺失多态性与糖尿病肾病相关性的研究进展[J]. 中日友好医院学报,2018,32(1):42-44.
9、 PERLMAN A S, JAMES M,WILKINSON P, et al. Serum inflammatory and immune mediators are elevated in early stage diabetic nephropathy[J]. Ann Clin Lab Sci, 2015, 45(3): 256-263. PERLMAN A S, JAMES M,WILKINSON P, et al. Serum inflammatory and immune mediators are elevated in early stage diabetic nephropathy[J]. Ann Clin Lab Sci, 2015, 45(3): 256-263.
10、 BALAKUMAR P, CHAKKARWAR V A, KUMAR V, et al. Experimental models for nephropathy[J]. J Renin Angiotensin Aldosterone Syst, 2008, 9(4): 189-195. BALAKUMAR P, CHAKKARWAR V A, KUMAR V, et al. Experimental models for nephropathy[J]. J Renin Angiotensin Aldosterone Syst, 2008, 9(4): 189-195.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录